DEXACORT
LOE ApproachingNDANASALAEROSOL
Approved
Dec 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXACORT is a nasal aerosol small-molecule corticosteroid approved in 1965 for nasal inflammatory conditions. The product delivers dexamethasone via intranasal route to reduce local inflammation and allergy symptoms. Generic formulations are available, making this a mature therapeutic option.
LOE Approaching
As LOE approaches, DEXACORT brand team focus will likely shift to cost-management, generic transition planning, and leveraging differentiated formulations if available to extend life cycle.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DEXACORT roles are predominantly commercial and regulatory in nature, focused on defending market share and managing generic transition. Limited clinical trial activity and approaching LOE mean fewer opportunities for clinical development or innovation-focused careers on this product.
Brand ManagerCommercial Operations Manager
Worked on DEXACORT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.